# Otsuka Pharmaceutical Development and Commercialization

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/otsuka-pharmaceutical-development-and-commercialization/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| OpenAlex ID | https://openalex.org/F4320333791 |
| Works | 269 |

## Funder papers

- [CKD progression, kidney failure, and mortality among US patients with IgA nephropathy](https://scholariq.org/papers/ckd-progression-kidney-failure-and-mortality-among-us-patients-with-iga/)
- [Incidence and Proportion of Primary Focal Segmental Glomerulosclerosis (FSGS) among a Racially and Ethnically Diverse Adult Patient Population between 2010 and 2021](https://scholariq.org/papers/incidence-and-proportion-of-primary-focal-segmental-glomerulosclerosis-fsgs/)
- [Mortality risk in patients with autosomal dominant polycystic kidney disease](https://scholariq.org/papers/mortality-risk-in-patients-with-autosomal-dominant-polycystic-kidney-disease/)
- [The incidence and prevalence of immunoglobulin A nephropathy in the United States](https://scholariq.org/papers/the-incidence-and-prevalence-of-immunoglobulin-a-nephropathy-in-the-united/)
- [Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease](https://scholariq.org/papers/patient-reported-outcomes-measures-polycystic-kidney-disease-burden-and-outcomes/)
- [Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review](https://scholariq.org/papers/burden-of-corticosteroid-therapy-in-patients-with-immunoglobulin-a-nephropathy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.